An injectable treatment for cellulite, collagenase clostridium histolyticum-aaes (Qwo, Endo International), is the first FDA-approved injectable treatment for cellulite.

The U.S. Food and Drug Administration (FDA) has approved collagenase clostridium histolyticum-aaes (Qwo, Endo International) for the treatment of moderate-to-severe cellulite in the buttocks in adult women.

"As Endo embarks on an exciting new journey into medical aesthetics, we look forward to bringing this innovative treatment to market through our Endo Aesthetics organization," says Blaise Coleman, president and CEO of Endo.

The injectable combines two collagenases, AUX-I and AUX-II, which are purified enzymes produced naturally by the clostridium histolyticum bacterium. Together, the enzymes degrade types 1 and 3 collagen by releasing the fibrous septae, which leads to an improvement in appearance and texture of the skin, according to the company.

The company expects the injectable to be available to aesthetic healthcare providers in the United States beginning in Spring 2021.

For more information about collagenase clostridium histolyticum-aaes, visit www.QWO.com.